PharmAust is a clinical-stage company developing therapeutics for humans & animals. They specialise in repurposing marketed drugs and lowering the risks and costs of development.
1. They are absolute experts at ….
PharmAust is the absolute expert at helping treat dogs with aggressive lymphoma by developing a novel safe, effective, affordable oral treatment families can use at home.
Phase 2 clinical trials of PharmAust’s Monepantel drug showed that at the optimum dose, dogs with treatment naïve B Cell lymphoma achieved stable disease or better as assessed by the administering vets, and side effects were minimal.
Repurposing an existing safe, approved and widely used drug for new, targeted cancer treatments can greatly reduce the time required to provide new therapies to terminally ill patients.
2. The one thing that makes them different from their competitors is….
The one thing that makes PharmAust different from its competitors is that it focuses on the discovery of novel uses for currently approved drugs.
PharmAust has discovered a potentially novel treatment for cancer in dogs and people. Monepantel represents a potential step change in canine lymphoma treatment versus costly and lengthy existing CHOP chemotherapy, which has significant side effects.
PharmAust hypothesises Monepantel works through an autophagy mechanism, inhibiting the mTOR protein which controls cell survival, and therefore can potentially have broad therapeutic applications.
For example, PharmAust is working with research partners to explore Monepantel’s potential action on the cancer-inducing HTLV-1 and COVID-19 respiratory viruses.
Phase 1 human trials of Monepantel to treat motor neuron disease, COVID-19 and a number of cancers are planned for 2023.
3. They can make your life easier by ….
PhamAust is currently recruiting dogs across Australian trial sites focused on dose optimisation before commencing a Phase 3 trial for registration prior to seeking to bring Monepantel to market.
Site centres can be found at https://www.pharmaust.com/petdogtrial/ and for any further information, please contact Dr Roger Aston, Executive Chairman, PharmAust. Email: [email protected] Tel: (08) 9202 6814